Press releases
May 10, 2021
Terasaki Institute Memorandum of Uderstanding
“The Terasaki Institute leads the world in the development of bioprintable, biopolymer-based technologies poised to revolutionize drug delivery, wearable and implantable devices. Jointly with HTL we expect to bring to life a new generation of biopolymer-based applications in critical sectors of precision and regenerative medicine,” added Maurizio Vecchione, Chief Innovation Officer of the Terasaki Institute for Biomedical Innovation.
Read more below.
To see our most recent news,
Read more
news from us
-
Articles October 3, 2024HTL Biotechnology will launch its White Paper at CPHI Milan!
We are excited to announce that the HTL Biotechnology team will be attending CPHI Milan and on this occasion, we will be launching our White Paper to celebrate 90 years of discovery of Hyaluronic Acid!
-
Articles October 1, 2024New Certification for HTL Biotechnology
We are proud to announce that HTL Biotechnology has recently received Halal certification for two of our key products: DNA and HANa.
-
Articles July 5, 2024HTL Biotechnology Secures Medical Device Registration in China
Sodium DNA Raw Material Main Document (Polynucleotides) registered as a medical device (number M2024199-000) in China.